Cytosorbents (NASDAQ:CTSO) Issues Earnings Results, Misses Estimates By $0.02 EPS

Cytosorbents (NASDAQ:CTSO) posted its earnings results on Wednesday, May 13th. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02), Zacks reports. The business had revenue of $8.86 million for the quarter, compared to analyst estimates of $9.40 million. Cytosorbents had a negative return on equity of 235.57% and a negative net margin of 31.85%.

Here are the key takeaways from Cytosorbents’ conference call:

• CytoSorbents reported Q1 2026 revenue of $8.9 million, up 2% year over year, with growth in direct international markets outside Germany offset by weakness in Germany and disruptions in the Middle East.
• International direct sales grew 13% year over year, which management said reflected better physician awareness, stronger execution, and improving adoption in key accounts.
• Gross margin was 69%, and the company said the slight decline was intentional because it slowed production to reduce inventory and improve working capital.
• The company said it now has clear FDA direction for DrugSorb-ATR, including a planned pre-submission for DOAC removal, though the new De Novo filing for ticagrelor removal may slip to late 2026 or early 2027 due to additional mechanistic data requests.
• Management highlighted growing clinical evidence for DrugSorb-ATR and CytoSorb, including STAR-T publication results showing the device was safe and reduced severe bleeding in CABG patients, plus upcoming presentations at major cardiovascular conferences.

Cytosorbents Stock Up 2.4%

CTSO opened at $0.48 on Thursday. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 4.70. Cytosorbents has a twelve month low of $0.37 and a twelve month high of $1.30. The stock has a market capitalization of $30.01 million, a price-to-earnings ratio of -2.57 and a beta of 1.35. The firm has a 50 day moving average price of $0.52 and a 200-day moving average price of $0.62.

Insider Transactions at Cytosorbents

In related news, CEO Phillip P. Chan purchased 251,136 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was bought at an average cost of $0.40 per share, for a total transaction of $100,454.40. Following the completion of the transaction, the chief executive officer directly owned 1,734,099 shares in the company, valued at $693,639.60. This represents a 16.93% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 7.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently bought and sold shares of CTSO. Goldman Sachs Group Inc. raised its stake in Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after purchasing an additional 79,535 shares during the last quarter. Citadel Advisors LLC boosted its holdings in shares of Cytosorbents by 127.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after buying an additional 36,790 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in Cytosorbents in the third quarter valued at approximately $161,000. Finally, Avenir Corp lifted its position in Cytosorbents by 2.9% during the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after acquiring an additional 147,261 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on CTSO. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research note on Wednesday, April 8th. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research report on Thursday, March 26th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $5.38.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.